NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/10/2024
Back to search
Official data from USPTO
JIXING
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
12/10/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
05/12/2022
Registration date
12/10/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/10/2024
Last transaction
12/10/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
03
Owner location
Shanghai, CN
Examiner
ABRAMS, JACQUELINE WILLETTE
Law office
L10
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized word "JIXING" in green with the design of a broken heart to the left in color with the left side of the heart being orange and the right side being green with a helix in between the two sides.
Holders and representatives
Holders
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Representatives
Erica Halstead WOMBLE BOND DICKINSON (US) LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of asthma; cholesterol reducers; antihypertensives; anti-diabetic pharmaceuticals; anti-diabetic preparations; antiarrhythmics; cardiovascular pharmaceutical preparations; pharmaceutical preparation for eye or intraocular surgery; ophthalmic pharmaceutical products; ophthalmic preparations; medical preparations for use with eyes; medicines for the treatment of cardiovascular diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; depuratives for the body; medicines for veterinary purposesveterinary diagnostic reagentsveterinary vaccinesAnti-infective products for veterinary useVeterinary preparationspain relief medication; Enzymes for veterinary purposes; biocides; disinfectant wipes; preparations to facilitate teething; diapers for pets; pharmaceutical candymedicated candies; medicines for human purposeshuman vaccine preparationsAntibiotics for human useanti-allergic and pain reduction medicines for treatment of illnesses for human purposes; pharmaceutical preparationspharmaceutical preparations for treatment of human illnessesheart disease and cancer; chemico-pharmaceutical preparationschemico-pharmaceutical preparations for treatment of human illnessesheart disease and cancer; ointments for pharmaceutical purposesantibioticsunburnanti-inflammatory ointments for pharmaceutical purposes; bronchodilating preparations; injectable pharmaceuticalsinjectable pharmaceuticals for treatment of anaphylactic reactions; tablets for pharmaceutical purposesmedicinal preparations for the mouth to be applied in the form of tablets and compressed tablets; tincture of iodine; herbal tinctures for medical purposes; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesterolemia
Class 42
Scientific research and development; development of pharmaceutical preparations and medicines; biomedical research services; medical research services; chemical research; biotechnology research; drug testing services; Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness; Software as a service (SAAS) serviceshosting software for use by others for use in database managementuse as a spreadsheetword processing; pharmaceutical drug research services; pharmaceutical drug development services
Publications
History of USPTO decisions and trademark events.
32 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/10/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/10/2024
PUBO
PUBLISHED FOR OPPOSITION
09/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/21/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/06/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/04/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
08/02/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/22/2024
GNSL
LETTER OF SUSPENSION E-MAILED
01/22/2024
CNSL
SUSPENSION LETTER WRITTEN
01/22/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/22/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/22/2024
ALIE
ASSIGNED TO LIE
01/22/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
08/30/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
06/08/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
06/08/2023
CNSI
SUSPENSION INQUIRY WRITTEN
06/08/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/30/2022
GNSL
LETTER OF SUSPENSION E-MAILED
11/30/2022
CNSL
SUSPENSION LETTER WRITTEN
11/30/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/29/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/29/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/29/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/31/2022
GNRT
NON-FINAL ACTION E-MAILED
05/31/2022
CNRT
NON-FINAL ACTION WRITTEN
05/31/2022
DOCK
ASSIGNED TO EXAMINER
05/30/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
05/18/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/17/2022
NWAP
NEW APPLICATION ENTERED
05/16/2022
Continuous trademark protection
Get notified about every new filing that threatens JIXING or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.